Alector to Present at the BofA Securities 2021 Virtual Health Care Conference
May 06, 2021 16:05 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman,...
Alector Reports 2021 First Quarter Financial Results and Provides Business Update
May 05, 2021 16:05 ET
|
Alector, Inc.
Enrollment ongoing for AL001 INFRONT-3 Phase 3 trial in frontotemporal dementia with a progranulin mutation and for AL002 INVOKE-2 Phase 2 trial in early Alzheimer’s disease patientsThree abstracts...
Alector to Present at Stifel’s 3rd Annual CNS Day
March 25, 2021 16:05 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz...
Alector to Present at the Barclays Global Healthcare Conference
March 04, 2021 16:05 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz...
Alector Reports 2020 Fourth Quarter and Full Year Financial Results and Provides Business Update
February 25, 2021 16:05 ET
|
Alector, Inc.
Continued execution across broad immuno-neurology portfolio, multiple milestones expected in 2021 Initiated AL001 INFRONT-3 Phase 3 trial in people with frontotemporal dementia with a progranulin...
Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer’s Disease
January 25, 2021 08:30 ET
|
Alector, Inc.
AL002 is the first product candidate targeting TREM2 in Phase 2 clinical developmentStudy will enroll early Alzheimer’s disease patients at up to 90 sites globallyAlzheimer’s disease is a devastating...
Alector Announces Departure of Chief Business Officer
January 20, 2021 16:15 ET
|
Alector, Inc.
Sabah Oney steps down from a role held since January 2018; joined Alector in October 2016The departure will be effective February 1, 2021; will assist in transition until May 3, 2021 SOUTH SAN...
Alector Provides 2021 Corporate Portfolio Update
January 07, 2021 16:05 ET
|
Alector, Inc.
Clinical trials advancing for Phase 3 in frontotemporal dementia and Phase 2 in Alzheimer’s disease Updated data from ongoing AL001 Phase 2 study in frontotemporal dementia expected in 2021The Company...
Alector to Present at the Stifel 2020 Virtual Healthcare Conference
November 11, 2020 16:05 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney,...
Alector Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 10, 2020 16:05 ET
|
Alector, Inc.
Global Phase 3 INFRONT-3 trial evaluating AL001 for treatment of frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) currently enrolling participantsOn track to initiate Phase 2 study...